I completely understand wanting as much research as possible, particularly when your own child has profound needs and you've been looking for answers.
I don't think it's fair to dismiss the protection concerns as potentially a convenient excuse. They weren't just objections from vocal autistic campaigners. The HRA and Research Ethics Committee themselves identified substantive questions around data use, withdrawal, safeguards and particularly consent for children and adults lacking capacity.
In fact, Spectrum 10K specifically wanted to recruit more autistic adults who lacked capacity because that group is underrepresented in research. I agree that they should be represented but the very fact they may be unable to give informed consent themselves means the ethical bar has to be higher, not lower.
Genetic data isn't just a saliva sample used to answer today's research question. It can potentially be retained, linked to health information and reused for future research that couldn't even have been anticipated when consent was given. That's why governance matters.
I don't see wanting research and wanting those protections as opposing positions. I want profoundly disabled autistic people included in research precisely because we need to understand them better, but I also want them afforded particularly strong protections because they're among the people least able to protect their own interests.
I know it's a huge cliché but data is the new oil. In fact, the more valuable and reusable the dataset is, the more important questions become about who controls it, who gets access, secondary research, commercial partnerships, retention periods, withdrawal, what happens if an organisation closes or is acquired, and whether genuinely meaningful consent was possible. There is a lot of data that you can change if it is acquired by someone else, but you can't change your genome. The biggest concern is that data being misused whilst not providing any clinical benefit to the participants.
Before this level of research continues, we need guaranteed and stronger safeguards in place with complete transparency about what will happen to that data.
I've also been thinking about how difficult it has been to develop and approve gene therapies for conditions where we do know the specific genetic cause. Sanfilippo syndrome, for example, has only just had its first FDA-approved treatment for type A after all the hurdles involved in developing UX111.
Sanfilippo A can be identified genetically and has a known disease mechanism. The hope with gene therapy, particularly if combined with newborn screening, is to intervene early enough to slow the progression of the disease and preserve development and quality of life before irreversible damage occurs. I know that the mechanism of this damage is due to enzyme function, which is distinctly different to what we know about autism so far.
Autism is very different. We know of many genes and variants associated with autism, but there isn't a single identifiable genetic cause of autism, and in most autistic people there isn't one specific mutation we can point to and target.
So even if gene therapies eventually become possible for some specific genetic forms of neurodevelopmental disability associated with autism, I struggle to see how that translates into a “cure for autism”. If we don't know which genetic mechanism we're targeting, can't reliably identify at birth who will develop which autistic phenotype, and much of that person's neurodevelopment has already occurred by the time autism becomes apparent, what exactly would the treatment be expected to reverse?